Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
SOLNA, Sweden, LOS ANGELES, Calif., and SHANGHAI, China, December 14, 2021
– Affibody AB, ACELYRIN, INC., and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis.The double-blind, placebo-controlled Phase 2 clinical trial, designed and conducted by Affibody AB, evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA. The interim analysis